Calcium, a vital mineral, is well-recognized for its essential role in the body's overall health, particularly in bone metabolism. This article delves into the integral role of calcium in bone metabolism and its implications for healthcare practice.
Calcium is the primary mineral found in bones and teeth, accounting for about 99% of the body's total calcium. It is crucial for bone health, contributing to bone mineral density and preventing osteoporosis. Calcium is also involved in the bone remodeling process, a balance between bone formation by osteoblasts and bone resorption by osteoclasts.
Calcium homeostasis is a tightly regulated process involving the intestines, kidneys, and bones. It is controlled by hormones such as parathyroid hormone (PTH), vitamin D, and calcitonin. Any disruption in this balance can lead to conditions like hypercalcemia or hypocalcemia, affecting bone health and various other physiological functions.
Understanding the role of calcium in bone metabolism has significant implications for healthcare practice. It underlines the importance of adequate dietary calcium intake and supplementation when necessary. It also emphasizes the need for regular monitoring of serum calcium levels in patients, particularly those at risk of bone-related disorders. Furthermore, it provides a foundation for the development of therapeutic strategies targeting calcium homeostasis for the treatment of bone diseases.
Calcium's role in bone metabolism is fundamental and multifaceted, with significant implications for healthcare practice. A comprehensive understanding of this role can guide healthcare providers in managing bone health, from prevention strategies to therapeutic interventions. Thus, calcium's role in bone metabolism is not just a biological fact but a critical component of effective healthcare delivery.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation